Sign In
Buy LXRX
$1.85
-0.0400 (-2.12%)
At Close: Jun 03, 2026
Why Shares of Lexicon Pharmaceuticals Are Up Tuesday
11:25am, Tuesday, 10'th Oct 2023
Lexicon just launched heart failure therapy Inpefa this year. The drug was approved by the FDA in May.
Lexicon Pharmaceuticals shares rise on Express Scripts support for Inpefa heart drug
07:47am, Tuesday, 10'th Oct 2023
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares jumped 9% in Tuesday pre-market trading after it announced that its Inpefa heart failure drug has been supported for Medicare patients by Express Sc
INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure
Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
04:30pm, Thursday, 07'th Sep 2023
THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25th Annual Global Investment Confe
THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2023 Earnings Call Transcript
10:01pm, Thursday, 03'rd Aug 2023
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Carrie Siragusa - Vice President of Marketing Lonnel Coats - Chief Executiv
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates
06:46pm, Thursday, 03'rd Aug 2023
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.16 per share a year ago.
Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023
04:01pm, Friday, 28'th Jul 2023
THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial results on Thursday, August 3rd, 2023 after the mark
Penny Stocks To Buy? 4 To Watch With Big News Now
11:02pm, Thursday, 15'th Jun 2023
Are you on the hunt for the next big thing? Ready to catch the wave before it crests?
Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference
04:01pm, Tuesday, 06'th Jun 2023
THE WOODLANDS, Texas, June 06, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies 2023 Global Healthcare Conference, taking place
4 Penny Stocks To Buy In June According To Insiders
03:20pm, Tuesday, 06'th Jun 2023
Penny stocks are often characterized by their high volatility. Their low price means that even small price changes can equate to significant percentage gains or losses.
Why Lexicon Pharmaceuticals Stock Crashed This Week
09:21am, Friday, 02'nd Jun 2023
With a new heart failure drug in hand, Lexicon Pharmaceuticals decided to raise capital this week, causing its shares to fall by double digits. The company plans on using the funds to support Inpefa's
Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval
12:10pm, Tuesday, 30'th May 2023
Lexicon's (LXRX) shares rise as it receives FDA approval for Inpefa, a once-daily oral tablet to treat a broad population of heart failure patients.
U.S. FDA approves Lexicon Pharma's heart failure drug
04:14pm, Friday, 26'th May 2023
The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc's drug as a broad treatment for all heart failure patients, including adults with type 2 diabetes, the company said
Wall Street's Counting on an FDA Nod for This Growth Stock to Nearly Double, but Should You?
06:50am, Thursday, 11'th May 2023
Lexicon's flagship medicine will go before regulators this month. There's a lot riding on getting an approval because it's running a bit low on cash.
